Home / Asia-Pacific / China / Life Sciences & Healthcare
side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare

As a participant in the life sciences and healthcare industry, you know that discovery and innovation are key to finding lasting health solutions. Yet due to the highly regulated nature of the industry, you - a corporate, investor or start-up - must overcome complex administrative, compliance and liability hurdles before your products and services can come to market.

With more than 480 experts, patent attorneys, scientists and academics across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your business. Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics.

With active memberships in the major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the life sciences sector. We regularly advise our clients on their day to day operational needs such as support with public sector procurement, patent prosecution and enforcement, commercial agreements, tax and transfer pricing, and regulatory advice. Equally, when you need life sciences specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.


Feed

08/08/2023
Circular on the Work Relating to the Im­ple­ment­a­tion of GB 9706.1-2020 and...
The National Medical Products Ad­min­is­tra­tion (“NMPA”) issued the Circular on the Work Relating to the Im­ple­ment­a­tion of GB 9706.1-2020 and Supporting Concurrent Standards and Special Standards (No...
12/06/2023
CMS updates Global Expert Guide to Digital health apps and telemedicine
Digitisation is advancing steadily. Its pioneering innovations challenge all parties involved.One of the most important aspects in this area is the huge potential that lies in the digitisation of health­care.In...
04/05/2023
Digital health apps and telemedicine in China
Digital Health Apps/Soft­ware 1. How is the software within digital health apps classified in your jur­is­dic­tion, and what reg­u­la­tion(s) apply? 1.1 Is it considered a “medical device” or a “product”...
Comparable
02/05/2023
CMS updates Expert Guide on cannabis law and legislation
CMS Expert Guide on cannabis law and le­gis­la­tion gives stakeholders detailed and updated information on the latest developments in cannabis regulation in key mar­kets. The Guide now covers two new jur­is­dic­tions:...
26/04/2023
Top developments and predictions in the Life Sciences & Healthcare sector...
In this round-up, we look back at the top developments over the last 12 months in the life sciences & healthcare sector, and we look to the future with our top predictions for the coming year for busi­nesses...
14/03/2023
China has acceded to the Hague Convention of 5 October 1961 Ab­ol­ish­ing...
On 8 March 2023, the People's Republic of China (the "PRC") has (finally!) acceded to the Hague Convention of 5 October 1961 Abolishing the Requirement of Legalisation for Foreign Public Doc­u­ments (the...
09/03/2023
CMS Expert Guide to ESG Compensation
In­cor­por­at­ing ESG KPIs into directors’ re­mu­ner­a­tionThe urgent need to place sus­tain­ab­il­ity at the heart of company strategy is inextricably linked to incentives provided to its directors and em­ploy­ees. This...
06/03/2023
Provisions on the Supervision and Ad­min­is­tra­tion of Drug Market Au­thor­iz­a­tion...
The National Medical Products Ad­min­is­tra­tion (“NMPA”) promulgated the Provisions on the Supervision and Ad­min­is­tra­tion of Drug Market Au­thor­iz­a­tion Holder Im­ple­ment­a­tion of the Main Re­spons­ib­il­ity...
01/03/2023
Provisions on the Supervision and Ad­min­is­tra­tion of Drug Market Au­thor­iz­a­tion...
The National Medical Products Ad­min­is­tra­tion (“NMPA”) promulgated the Provisions on the Supervision and Ad­min­is­tra­tion of Drug Market Au­thor­iz­a­tion Holder Im­ple­ment­a­tion of the Main Re­spons­ib­il­ity...
28/02/2023
New EU sanctions against Russia
On 25 February 2023, one year after Russia started its invasion of Ukraine, the EU adopted its tenth sanctions package against Russia. Together with the existing sanctions the European Commission considers...
28/02/2023
Ad­min­is­trat­ive Regulations on Enterprise Im­ple­ment­a­tion of the Main Re­spons­ib­il­ity...
The National Medical Products Ad­min­is­tra­tion (“NMPA”) promulgated the Provisions on the Supervision and Ad­min­is­tra­tion of Enterprise Im­ple­ment­a­tion of the Main Re­spons­ib­il­ity of Medical Device Quality...
28/02/2023
Ad­min­is­trat­ive Regulations on Enterprise Im­ple­ment­a­tion of the Main Re­spons­ib­il­ity...
The National Medical Products Ad­min­is­tra­tion (“NMPA”) promulgated the Provisions on the Supervision and Ad­min­is­tra­tion of Enterprise Im­ple­ment­a­tion of the Main Re­spons­ib­il­ity of Medical Device Quality...